GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Strides Pharma Science Ltd (BOM:532531) » Definitions » E10

Strides Pharma Science (BOM:532531) E10 : ₹22.80 (As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Strides Pharma Science E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Strides Pharma Science's adjusted earnings per share data for the three months ended in Dec. 2024 was ₹9.550. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹22.80 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Strides Pharma Science's average E10 Growth Rate was -51.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-04-05), Strides Pharma Science's current stock price is ₹622.65. Strides Pharma Science's E10 for the quarter that ended in Dec. 2024 was ₹22.80. Strides Pharma Science's Shiller PE Ratio of today is 27.31.

During the past 13 years, the highest Shiller PE Ratio of Strides Pharma Science was 33.72. The lowest was 1.90. And the median was 4.09.


Strides Pharma Science E10 Historical Data

The historical data trend for Strides Pharma Science's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strides Pharma Science E10 Chart

Strides Pharma Science Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 67.53 61.96 39.35

Strides Pharma Science Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.90 39.35 19.76 22.19 22.80

Competitive Comparison of Strides Pharma Science's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strides Pharma Science's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's Shiller PE Ratio falls into.


;
;

Strides Pharma Science E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Strides Pharma Science's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=9.55/158.3229*158.3229
=9.550

Current CPI (Dec. 2024) = 158.3229.

Strides Pharma Science Quarterly Data

per share eps CPI Adj_EPS
201503 1.840 97.163 2.998
201506 1.320 99.841 2.093
201509 4.430 101.753 6.893
201512 5.510 102.901 8.478
201603 20.930 102.518 32.323
201606 2.910 105.961 4.348
201609 7.770 105.961 11.610
201612 5.010 105.196 7.540
201703 12.540 105.196 18.873
201706 0.060 107.109 0.089
201709 0.960 109.021 1.394
201712 9.540 109.404 13.806
201803 63.430 109.786 91.472
201806 -0.480 111.317 -0.683
201809 -1.340 115.142 -1.843
201812 32.760 115.142 45.046
201903 5.300 118.202 7.099
201906 0.410 120.880 0.537
201909 15.940 123.175 20.488
201912 10.480 126.235 13.144
202003 -22.770 124.705 -28.908
202006 11.560 127.000 14.411
202009 9.030 130.118 10.987
202012 4.220 130.889 5.104
202103 5.130 131.771 6.164
202106 -22.880 134.084 -27.016
202109 -18.120 135.847 -21.118
202112 -13.550 138.161 -15.527
202203 3.260 138.822 3.718
202206 -15.130 142.347 -16.828
202209 2.540 144.661 2.780
202212 -8.860 145.763 -9.623
202303 -1.040 146.865 -1.121
202306 -0.790 150.280 -0.832
202309 -14.540 151.492 -15.196
202312 5.420 152.924 5.611
202403 2.030 153.035 2.100
202406 7.620 155.789 7.744
202409 10.120 157.882 10.148
202412 9.550 158.323 9.550

Add all the adjusted EPS together and divide 10 will get our e10.


Strides Pharma Science  (BOM:532531) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Strides Pharma Science's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=622.65/22.80
=27.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Strides Pharma Science was 33.72. The lowest was 1.90. And the median was 4.09.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Strides Pharma Science E10 Related Terms

Thank you for viewing the detailed overview of Strides Pharma Science's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Strides Pharma Science Business Description

Traded in Other Exchanges
Address
Strides House, Bannerghatta Road, Bilekahalli, Bengaluru, KA, IND, 560 076
Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market plan focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.

Strides Pharma Science Headlines

No Headlines